Pfizer Secures Up to $1.5 Billion from Blackstone Life Sciences to Fund US Obesity Drug Berobenatide
Pfizer secures up to $1.5B from Blackstone Life Sciences to fund berobenatide, a first-in-class monthly GLP-1 obesity drug, with 10 Phase 3 trials planned.
Research Desk
Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a total of USD 1.5 billion of development costs through 2028 for berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions.
In exchange for the funding, Blackstone will be eligible to receive milestone-based payments.
Pfizer Retains Full Control Under Blackstone Funding Agreement
Those payments are subject to U.S. regulatory approval of the monthly dosing of injectable berobenatide monotherapy for chronic weight management and to the achievement of certain commercial sales milestones. Any milestone payments, if earned, will be payable to Blackstone over a multi-year period.
Under the terms of the agreement, Blackstone does not acquire any rights or ownership in berobenatide, and Pfizer retains full operational control and decision-making with respect to the berobenatide program.
Funds managed by Blackstone's perpetual private equity strategy, BXPE, will invest alongside funds managed by Blackstone Life Sciences as part of the transaction.
Pfizer Frames the Deal as Pipeline-Friendly Financing
Cecile Guegan, Chief Financial Officer and Executive Vice President of Pfizer, said the company's aim is to bring important new medicines to patients while taking a disciplined approach that pairs internal research investments with targeted investment from capital partners.
According to Guegan, the announcement helps Pfizer advance its comprehensive obesity program and maintain the financial capacity and flexibility to invest in its broader pipeline across all therapeutic areas.
Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences, said the firm is pleased to further expand its relationship with Pfizer and support the broad and rigorous development of berobenatide as the anchor of Pfizer's cardiometabolic pipeline.
He described the collaboration as a good example of Blackstone's leadership in providing capital solutions at scale to advance important medicines and technologies to patients.
A Broad Development Program Planned for 2026
Berobenatide, also identified by the code PF'3944, is an investigational, potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide being studied for chronic weight management and obesity-related comorbidities.
The comorbidities under study include knee osteoarthritis and obstructive sleep apnea. Pfizer plans to advance more than 20 trials for obesity and related comorbidities in 2026. That figure includes 10 ongoing and planned Phase 3 trials for berobenatide.
The company said a growing body of evidence supports advancing an extensive development program for berobenatide as a monotherapy and in combination with various Nutrient-Stimulated Hormone (NuSH) peptides, including amylin analogs.
Context for the Agreement
The press release describes the funding arrangement as part of Pfizer's broader obesity and cardiometabolic strategy, with berobenatide positioned as the anchor of that pipeline.
The announcement was issued jointly from New York and Cambridge, Massachusetts.
Tracked in the database
Pharmaceutical Industry Financing · North America
Pharmaceutical Industry Financing
North America
Chemical
12 November 2026
2 min read
Tagged
Also read
Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany
LOTTE Biologics Signs First Commercial Manufacturing Agreement for Songdo Plant 1 in South Korea
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.